Details of the Drug Combinations

General Information of This Drug (ID: DMSB068)

Drug Name

PF-04449913 DMSB068

Synonyms

Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2

Indication

Disease Entry	ICD 11	Status	REF
Chronic myelomonocytic leukaemia	2A40	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Daunorubicin + PF-04449913	DCD4PRD	Daunorubicin	Acute Myeloid Leukemia	[3]
Decitabine + PF-04449913	DCJJC2S	Decitabine	Acute Myeloid Leukemia	[3]
PF-04449913 + Azacitidine	DCGSXOM	Azacitidine	Acute Myeloid Leukemia	[4]
Decitabine + PF-04449913	DC4SUAZ	Decitabine	ACUTE MYELOID LEUKEMIA	[5]
PF-04449913 + Azacitidine	DCAYEPZ	Azacitidine	Acute Myeloid Leukemia	[6]
------------------------------------------------------------------------------------

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT01546038) A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
4	ClinicalTrials.gov (NCT02038777) A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
5	ClinicalTrials.gov (NCT04051996) GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
6	ClinicalTrials.gov (NCT04842604) Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML